Evaluating large language models (LLMs) is crucial as LLM-based systems become increasingly powerful and relevant in our society. Rigorous testing allows us to understand an LLM’s capabilities, limitations, and potential biases, and provide actionable feedback to identify and mitigate risk. Furthermore, evaluation processes are important not only for LLMs, butContinue Reading
As enterprises increasingly embrace generative AI , they face challenges in managing the associated costs. With demand for generative AI applications surging across projects and multiple lines of business, accurately allocating and tracking spend becomes more complex. Organizations need to prioritize their generative AI spending based on business impact andContinue Reading
U.S. stocks on Friday marched higher, helped by a rebound in megacap technology names and more encouraging developments on the inflation front. A rotation out of heavyweights such as the “Magnificent 7” club weighed on the benchmark S&P 500 (SP500) and the Nasdaq Composite (COMP:IND) in the previous session, butContinue Reading
Iryna Drozd Adicet Bio (NASDAQ:ACET) stock jumped 10% Monday morning after the company said it had received FDA fast track designation for its CAR-T cell therapy candidate ADI-270 for the treatment of metastatic/advanced clear cell renal cell carcinoma, a type of kidney cancer. The designation was granted for the treatmentContinue Reading
JHVEPhoto The U.S. FDA has granted Inozyme Pharma (NASDAQ:INZY) Fast Track designation for NZ-701, its treatment of ABCC6 Deficiency. The company noted it hopes to have an agreement with regulators on a pivotal trial design by the end of the year. In April, Inozyme released promising topline results from anContinue Reading
